DBS Therapy

MEDTRONIC DBS FOR PARKINSON’S DISEASE

Deep brain stimulation (DBS) helps control the movement symptoms of Parkinson’s disease, including tremor, slowed movement and stiffness.

LEARN MORE

EMPOWER YOURSELF

Understand Parkinson’s disease and learn more about
deep brain stimulation as a treatment option.

LEARN MORE
wpd-stock-hands

DBS Therapy

Every day, we want to feel life in all its colours and shades. But little by little, Parkinson’s chips away those moments, those minutes and so many of life’s simple pleasures.

But you are not alone. Medtronic DBS therapy can help you improve your quality of life and feel more like your old self again.

The biggest thing for me is I have my smile back.

BE MORE YOU, LIKE ANDY

YOUR DBS RESOURCES AND SUPPORT

Medtronic Support Link℠ education programme for people with Parkinson’s

Support Link℠ makes it easy to get answers to your questions about deep brain stimulation (DBS).

You can talk on the phone with someone who has received DBS, watch videos from experts, prepare yourself to discuss DBS with your doctor and much more.

READ MORE
PD Home Map

MORE THAN <br>150,000 <br>people with <br>movement <br>disorders  

HAVE BENEFITED <br>FROM MEDTRONIC

DBS THERAPY  <br>TO DATE

IN MORE THAN  <br>73 COUNTRIES

85–89% OF PEOPLE

with Parkinson’s who have DBS surgery experience improvements, if candidates are carefully selected and if the lead is correctly placed.1

EXPLORE THE BENEFITS AND SAFETY INFORMATION OF DBS
Home_Section_5_Image1

I still feel better now after 10 years of DBS than before my surgery.

BE MORE CONFIDENT, LIKE LAURA

LEARN HOW OUR DBS PRODUCTS
WORK FOR YOU

LEARN MORE
DBS Product Family
DBS Therapy

7 out of 10 people with
Parkinson's who are ELIGIBLE
FOR DBS THERAPY MAY
NEED AN MRI FOLLOWING
THEIR IMPLANT2

DOWNLOAD OUR MRI FLYER

References

1

Medtronic supplemental analysis: supplement to EPDA website update re patient barriers and claims-v17-Sept-2015

The 'gold standard' of evaluating the success rate of DBS is based on the overall motor function evaluation using the UPDRS III scale. The scientifically accepted method for evaluation of the MCIC (minimally clinically important change) is at least 5 points in the UPDRS III scale. The evaluation of 'off medication' allows reflection of the impact of DBS, albeit an artificially created 'off' condition. It has not been typically reported in the publications, but we have completed the above additional analyses of the databases available in both the published evidence (only randomised control trials have been considered for this). The above analysis works for Medtronic devices only.

2

Based on recommendations by European and national medical societies

Analyses based on PD comorbidities recommended for MRI in Europe. The % was calculated for a real-life PD population potentially eligible for DBS, from US commercial health insurance database (Conroy et al, conference presentation, ECR 2015, Vienna).